At the time of writing, Ascendis Pharma A/S ADR [ASND] stock is trading at $151.26, down -1.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The ASND shares have gain 26.87% over the last week, with a monthly amount glided 10.41%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ascendis Pharma A/S ADR [NASDAQ: ASND] stock has seen the most recent analyst activity on September 05, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $180 for it. Previously, TD Cowen upgraded its rating to Buy on June 25, 2024, and elevated its price target to $175. On May 31, 2024, Stifel initiated with a Buy rating and assigned a price target of $200 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $150 on December 20, 2023. Oppenheimer downgraded its rating to Perform for this stock on April 05, 2023. In a note dated April 04, 2023, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $151 to $108.
For the past year, the stock price of Ascendis Pharma A/S ADR fluctuated between $85.29 and $161.00. Currently, Wall Street analysts expect the stock to reach $189.07 within the next 12 months. Ascendis Pharma A/S ADR [NASDAQ: ASND] shares were valued at $151.26 at the most recent close of the market. An investor can expect a potential return of 25.0% based on the average ASND price forecast.
Analyzing the ASND fundamentals
According to Ascendis Pharma A/S ADR [NASDAQ:ASND], the company’s sales were 343.17M for trailing twelve months, which represents an -24.87% plunge. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -1.11%, Pretax Profit Margin comes in at -1.5%, and Net Profit Margin reading is -1.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is 2.52 and Total Capital is 3.96. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 149.56 points at the first support level, and at 147.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 154.24, and for the 2nd resistance point, it is at 157.23.
Ratios To Look Out For
It is important to note that Ascendis Pharma A/S ADR [NASDAQ:ASND] has a current ratio of 0.74. On the other hand, the Quick Ratio is 0.44, and the Cash Ratio is 0.31. Considering the valuation of this stock, the price to sales ratio is 25.28.
